buy cannabis seeds
buy marijuana seeds
buy CBD oil

GW Pharmaceuticals Announces New US Patent Allowance


GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/607,897, a patent which protects delivery of its Sativex® product formulation.

sativex usa patent patents cancer pain delivery sprayThe subject patent specifically covers an improved method of sublingual delivery to a human consisting of administering an extract of cannabis in ethanol and propylene glycol. The formulation may be dispensed using an aerosol spray. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent from this application will provide an exclusivity period until March 2021.

This new patent is one of at least seven different patent families containing one or more pending or issued patents relating to the Sativex formulation, the extracts from which Sativex is composed, the extraction technique and the therapeutic use of Sativex. GW’s granted patents and pending applications (if they were to issue) relating to Sativex would expire on various dates between 2021 and 2026, excluding possible patent term extensions. There are an additional 154 issued patents covering Sativex and GW’s product pipeline outside of the US.

In the indication for the treatment of cancer pain, GW has obtained a patent in the US, entitled “Pharmaceutical Compositions for the Treatment of Pain,” (Patent number 7,968,594) which expires in September 2026. Sativex is currently in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and elsewhere.

“This Notice of Allowance covering the Sativex pharmaceutical formulation further strengthens the patent position for Sativex in the United States, the world’s largest pharmaceutical market,” stated Justin Gover, GW’s Chief Executive Officer. “Sativex is not only protected by seven different patent families but its exclusivity is further enhanced by other forms of protection such as plant variety rights and proprietary know-how.  We believe that this matrix of intellectual property provides GW with a unique position to benefit from the rich promise within the field of cannabinoid therapeutics.”

GW’s intellectual property portfolio includes multiple patent families with issued and/or pending claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights, know-how and trade secrets.